A retrospective study comparing the effective sequencing strategy between abiraterone and docetaxel in metastatic castration - resistant prostate cancer in Ramathibodi Hospital, Thailand. Prostatic Neoplasms, Castration-Resistant, Drug Sequencing, Real-World Evidence
Conditions
Interventions
Abiraterone acetate was administered as first-line treatment for metastatic CRPC, followed by docetaxel as second-line therapy.,Docetaxel was administered as first-line treatment for metastatic CRPC,
Treatment,Treatment
First line with Abiraterone acetate,First line with Docetaxel
Sponsors
None listed
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adult male patients whose age > 18 years old 2. Diagnosed with metastatic castration-resistant prostate cancer (mCRPC) who have received both standard systemic therapies, including abiraterone acetate and/or docetaxel.
Exclusion criteria
Exclusion criteria: 1. Patients with non-adenocarcinoma histology. 2. Patients who have had prior chemotherapy in the hormone-sensitive setting, and receipt of investigational therapies, all of which may confound treatment effects. 3. Patients with baseline central nervous system involvement 4. Patients who were active concurrent with other malignancies. 5. Patients with a limited life expectancy (<3 months) at the initiation of mCRPC treatments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival Jan 2015 - Until death or at the end of completion date ( 19 April 2026) Day | — |
Secondary
| Measure | Time frame |
|---|---|
| Prostate-Specific Antigen Response 3, 6, 9, 12 months after treatment Percentage | — |
Countries
Thailand
Contacts
Public ContactPhichai Chansriwong
Ramathibodi Hospital
Outcome results
None listed